BLADDER CANCER
 
Pembrolizumab granted new bladder Ca indication
The FDA has approved the anti-PD-1 therapy pembrolizumab (KEYTRUDA) as monotherapy for the treatment of patients with BCG-unresponsive, high-risk, nonmuscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
Dr. Balar discusses treatment
ADVERTISEMENT
 
FDA approves enfortumab for locally advanced or metastatic urothelial Ca
The FDA has granted accelerated approval to enfortumab vedotin-ejfv (PADCEV) for the treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and a platinum-containing chemotherapy before or after surgery or in a locally advanced or metastatic setting.
Learn more
 
ADVERTISEMENT
Start 2020 with a Cysview® Reference Center Visit
See hexaminolevulinate HCl in action in the operating room or clinic setting. Get answers and tips from an expert user. Travel and meal expenses are reimbursed. RSVP to discuss available dates and locations.
 
MORE FROM UROLOGY TIMES
 
Agent for high-grade NMIBC meets primary endpoint in phase III trial
How the Cancer Genome Atlas has impacted bladder Ca management
ADVERTISEMENT
Imaging for challenging cases and options for treatment
Oliver Wiseman, MD, discusses how detailed imaging techniques, including contrast CT and reconstructed models, equipped him to identify the location and size of a patient’s calyceal diverticulum. Watch this case study now
 
JOB OPPORTUNITIES
 
NY-WNY Urology Associates
VT-University of Vermont
VT-University of Vermont